Bill intelligence
S. 4987, Transparency and Oversight Mandate. Quorum's AI analysis reads it as a net benefit — and names who gains.
S. 4987 · Net good
Prescription Drugs
What it does
This bill requires the Federal Trade Commission to produce annual reports on foreign investment in U.S. pharmaceutical companies, drug manufacturing, and DNA sequencing/storage technology.
The analysis did not isolate a single beneficiary class.
The trade-off
Annual reporting may create a de facto registry of foreign pharmaceutical ownership, potentially informing future CFIUS (Committee on Foreign Investment in the US) enforcement or legislative restrictions without explicitly authorizing them.
Transparency scores 78%, with a medium warning level and no detached riders.
Who is behind it
Filed by Elizabeth Warren. Cosponsored by Kirsten Gillibrand and Rick Scott.
Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
SOURCE: QUORUM BILL ANALYSIS (LLM, FULL TEXT) · QUORUM BILL TRANSPARENCY ANALYSIS